Follow this and additional works at: https://uknowledge.uky.edu/psychiatry_facpub Since empirical evidence suggests that the linear model may adequately describe drugs and patient populations, and linear models are easier to handle than the nonlinear models traditionally used in population pharmacokinetics, our results highlight the potential applicability of linear mixed models to dosage computations and personalized medicine.
Introduction
In the pharmacological treatment of some chronic illnesses, the clinician must search for an appropriate drug dosage D that, after being administered during a pre-specified time period to a particular patient, will maximize the probability that a continuous pharmacokinetic or pharmacodynamic response Y D takes a value between two pre-specified values l 1 and l 2 . Examples of these treatments are those based on drugs having a narrow therapeutic range, which is the range of plasma (or blood) drug concentrations that yield the desired pharmacological effect without toxicity; in this case, a pharmacokinetic response of interest (Y D ) is usually the steady-state trough plasma drug concentration in the patient, which is measured during routine therapeutic drug monitoring (TDM) (Shirrell et al., 1999) . For instance, when administering the antipsychotic drug clozapine to a patient with schizophrenia, the clinician must make efforts to avoid plasma clozapine concentrations in the patient reaching very low or high values, since low concentrations will not reduce psychotic symptoms and high concentrations will increase the risk of severe sedation, seizures and other undesirable effects (Sabaawi et al., 2006) .
In this example, D is clozapine dosage and Y D is plasma clozapine concentration.
Another (classic) example in which the plasma (or blood) concentration of the treatment drug is a response of interest may be found during the treatment for heroin addiction based on methadone. An effective methadone-maintenance treatment requires that the minimum methadone concentration in the patient's blood be kept above the threshold of heroin-withdrawal symptoms, and that the maximum concentration be kept below the threshold of the appearance of narcotic effects (Dole, 1980) . Whereas low methadone concentrations do not overcome heroin-withdrawal symptoms and also increase the risk of relapsing into heroin use, high concentrations will sedate the patient, preventing him/her from enjoying a normal and fruitful life. In this example, D is methadone dosage and Y D is blood methadone concentration.
There are pharmacological treatments in which the clinician wants to control a continuous response other than plasma concentration of the treatment drug. An example is the use of the anti-coagulant drug warfarin to prevent blood clotting in patients with risk of thrombotic episodes. To monitor the treatment and adjust warfarin dosage, regular blood tests must be performed to measure the clotting tendency of the patient's blood; this measure is usually given as an international normalized ratio, INR (Cuadrado et al., 2000) . The objective of dosage adjustment is to find an optimum dosage that produces an anti-coagulation intensity between minimum and maximum pre-specified values. Lower dosages than this minimum may not be effective (putting the patient at risk of a new thrombotic episode), and higher dosages than the maximum may produce serious hemorrhages. Here, D is warfarin dosage and Y D is the INR, which is a pharmacodynamic response of interest.
In the above examples and those similar, the clinician usually assumes that the patient's continuous response (drug plasma or blood concentration in the first 2 examples and INR in the third example) will become stable after administering a constant drug dosage for a known, fixed period of time. Further, the clinician must take steps to find a dosage that, after being administered for that period of time, maximizes the probability that the patient's response reaches a value that is not too low or too high, and therefore maximizes the chance of relieving the illness symptoms and minimizes the risk of experiencing undesirable or toxic effects. Finding this dosage is usually difficult, since there is usually wide variability across individual patients in response to the same pharmacological treatment. This response variability may be due to personal (e.g., age or gender), genetic, or environmental (e.g., drug-drug interactions) influences on pharmacokinetic and/or pharmacodynamic parameters, or even to patient compliance (Nies, 2001) . Efforts have been made to develop drug-dosage individualization procedures based on statistical models that take into account this variability (for a review, see Diaz et al., 2007) . Among these procedures, those based on mixed effects models seem to be very promising.
The application of mixed effects models to the individualization of drug dosages was pioneered by Sheiner and his collaborators (see Vozeh et al., 1981; Sheiner and Beal, 1982) . Underlying this application is the basic idea that a random coefficient in a mixed effects model can be viewed as a parameter that is a characteristic constant for a particular patient in the population of patients, but that varies across patients (see Sheiner and Beal, 1980; Whiting et al., 1986) . According to this idea, the variability of a random coefficient reflects a real variation in the biological and environmental variables that shape each person in the population as an individual; variability is not a mere mathematical artifact for dealing with a population's heterogeneity. Thus, a mixed effects model includes parameters with constant values representing the whole population (fixed effects) and parameters with varying values whose particular values represent particular patients (random effects). Usually, these parameters measure or reflect patients' pharmacokinetic or pharmacodynamic characteristics. For a history of both the theory and applications of mixed effects models in pharmacology, see Pillai et al., 2005. In practice, any drug dosage individualization procedure based on a population mixed effects model utilizes Bayes' theorem. Before applying a procedure to a particular patient, the fixed effects and variance-covariance matrices of the random effects and errors must be estimated by using one or more samples of patients, or using previous pharmacological knowledge. Then, the estimated distribution of the random coefficients is conceived of as a prior distribution for these coefficients, and a few response measurements (e.g., drug plasma concentrations) from the patient are used to compute the conditional distribution of the random coefficients given those measurements. A summary measure of this conditional distribution, such as its mean or mode vector, is considered a predictor of the true values of the patient's coefficients, and therefore used to compute the patient's individualized dosage. According to this methodology, which is usually called "Bayesian feedback", a prior distribution models real-world random variables (i.e., models the variability of some pharmacokinetic or pharmacodynamic parameters in the patient population). Thus, the prior distribution is not interpreted as a representation of the clinician's system of subjective beliefs about hypothetical, constant population parameters, which would be an orthodox, classic interpretation of the prior distribution underlying Bayes' theorem. Failing to recognize that statistical practice may profit from these two different philosophical conceptions of prior distributions, rather than from the latter one alone, may have contributed to a misunderstanding of the Bayesian feedback methodology in the statistical community, which struggled for decades to understand the philosophical implications of Bayes' theorem. Diaz et al. (2007) considered the individualization of a drug dosage when the natural log of steady-state drug plasma concentration-to-dosage ratio can be described using a random intercept linear model. In their model, it is assumed that no covariate has a random effect. Specifically, the studied model was
where Y D is a trough steady-state drug plasma concentration, D is the steady-state dosage, X is a vector with r covariates, β is a vector with regression coefficients that are population constants, and α is a characteristic constant of each patient. At the population level, it is assumed that α is a N(μ α , σ consists of a series of steps that the clinician should follow in order to find an appropriate dosage for a particular patient, assuming that model (1) adequately represents the patient population. Before applying the algorithm to a particular patient, the population parameters β, μ α , σ 2 α and σ 2 have to be estimated using a sample of patients.
A simulation study using a clozapine model built with a US patient sample suggested that the algorithm will perform reasonably well, even including the possibility that parameter estimates are not very close to the true parameter values, and even if clozapine dosages are rounded to the closest multiple of the smallest dosage available from clozapine manufacturers, 25 mg/day (2007).
A difficult problem when individualizing a drug dosage using a population mixed effects model is to decide how many drug plasma concentrations to obtain from the patient, such that an optimum dosage for the patient is computed. Solutions to this problem usually are ad hoc or lack clear justifications. However, Diaz et al. (2007) provided a theoretical framework that enables a solution to this problem for model (1) . They introduced the concept of ω-optimum dosage for a patient with metabolic index γ, which, for ω close to 1, is essentially a dosage D that nearly maximizes the conditional probability
is the range of desired plasma concentrations. Thus, the optimum number of plasma concentrations that must be obtained from the patient is the one that allows computing an ω-optimum dosage for a pre-specified, high proportion of patients in the population. (1) that included transformed covariates and both peak and trough steady-state plasma concentrations. They proposed using their linear model to investigate the sensitivity of results from population pharmacokinetics analyses, and studied 3 drugs (2 biologicals and 1 small molecule) using large, multinational patient samples. 
Applicability of Diaz et al.'s algorithm in a more general setting
This study considers the model
where is defined as in model (1), Z and X are vectors with k and r (possibly transformed) clinical or demographic covariates, respectively, β is a vector of regression coefficients that are population constants, and d is a population constant. Here, ψ and η are characteristic constants of a particular patient; they vary from patient to patient.
At the population level, it is assumed that ψ is a N(μ ψ , σ
has a joint normal distribution, and that (ψ, η) and are independent from each other. Please note that whereas X includes only covariates with fixed effects (the elements of β), Z includes covariates that have fixed effects (the elements of μ η ) and random effects (the elements of η −μ η ).
Therefore, in order for β and μ η to be identifiable, we assume that none of the covariates in X are in Z, and vice versa. In the traditional terminology of mixed linear models, For a fixed value of Z, if we denote
Thus, for fixed Z, model (3) Step 1: By using α 1 = μ α (Z) and
Next, administer D 1 to the patient during an appropriate time period so that the response becomes stable, and then measure the stabilized response Y D 1 .
Step i, i ≥ 2: By using the dosage-response pairs (
which were obtained in the i − 1 previous steps, compute the i-th dosage
where α i is a predictor of α given by
with
and λ i , i ≥ 1, defined by Eq. (12) Suppose that a population of patients satisfy model (2) , and that a particular patient from the population has characteristic constants ψ and η and, therefore, a
. Assume that Diaz et al.'s algorithm is applied to this
patient. An important question is: How many algorithm steps are necessary to obtain an appropriate dosage for the patient? This question is answered by using the concept of ω-optimum dosage (Diaz et al., 2007) . Specifically, in the context of model (2), for 0 < ω < 1, an ω-optimum dosage for the patient is a dosage D that satisfies
where
. Thus, when model (2) holds, the largest attainable probability that the response of the patient reaches a value within the target range
is m, and the minimum number of algorithm steps that are necessary to reach an ω-optimum dosage for the patient is I(γ, ω), where m and I(γ, ω) are defined by Eqs. (14) and (16) depending on γ and ω, I(γ, ω) depends on both m and ρ, where ρ is given by Eq. (7) if model (2) holds.)
In practice, since the patient's γ is unknown, it is necessary to stop the algorithm at the earliest step that yields an ω-optimum dosage for at least a fraction p of patients, 0 < p < 1. When model (2) holds, the minimum number of algorithm steps that are necessary to obtain an ω-optimum dosage for at least p × 100 % of the patients in the population is i * , which is defined by Eq. (18) Please note that, in the context of model (2), i * depends on the particular value that Z takes on in the patient, although i * does not depend on X. Moreover, although the definition of an ω-optimum dosage given by (9) formally depends on an infinite sequence of future dosages, only a finite number of administered dosages is needed to compute a dosage that has at least a p × 100 % possibility of being ω-optimum for the patient. This number is i * − 1.
A comparison with therapeutic drug monitoring
Diaz et al.'s algorithm may be considered an optimal method for dosage adjustment in a TDM setting when the patient belongs to a population that satisfies model (2) and Y D is drug plasma concentration. To understand why this may be so, let us compare Diaz et al.'s algorithm with a popular method for dosage adjustment which is advocated in a number of pharmacology textbooks. This method, which assumes linear pharmacokinetics, adjusts the patient's dosage using the formula
where C 0 is a target drug steady-state trough concentration. Let A and B be two patients from a population that satisfies model (2) random errors that may be reasonably assumed to be mutually independent and independent of the i 's. But, for i ≥ 2,
where Thus, if C 0 = C * 0 , then given γ, then inequality (12) is also valid for i = n + 1, provided that D n+1 is computed using Eqs. (5) and (6) however, is to ensure that the probability of the drug concentration falling within the target range is maximized each time a dosage is computed.
Application to clozapine individualization
Clozapine is an antipsychotic drug used to treat patients with severe schizophrenia. These random effects were statistically significant at the 0.05 level of significance. Also, Akaike information criteria were 405.3 and 385.6 for the model in Diaz et al. (2008) and the model with covariate random effects, respectively, suggesting that the latter fit better. Table 1 , which includes random effects for smoking (Z 1 ) and taking fluoxetine (Z 2 ), we obtain m = 0.90. Moreover, by using Eq. (7) with Table 1 
Computer simulations assuming accurate parameter estimates
We conducted a simulation study that compared the performance of Diaz et al.'s algorithm with that of an iterative application of formula (10) , assuming that the model described in Table 1 is a reasonable representation of the patient population, and using l 1 = 350 ng/ml and l 2 = 600 ng/ml. The main purpose of these simulations was to explore differences between the two approaches, using realistic values for model (2) parameters. The issue of whether and how parameter estimates can be improved is out of the scope of this article and is the topic of a great deal of research (see, e.g., Verbeke (4) and (5), or with formula (10), were rounded to their closest multiple of 25 before "administering" them to the patients (that is, before using the model to compute the resultant plasma clozapine concentrations). All dosages were of at least 25 mg/day. (10), in that the algorithm may produce substantially higher proportions of patients reaching the target clozapine concentration range.
A comparison with traditional TDM under parameter estimation errors
In Section 5, the parameters used to compute dosages with Diaz et al.'s algorithm were the same as those used to simulate the subjects' pharmacokinetic responses to dosages from both the algorithm and formula (10) . Thus, it was assumed that the available parameter estimates were very precise estimations of the true model parameters. In practice, parameter estimates must be used by the clinician to compute dosages with parameters. Letθ i be the estimate of ϑ i and se(θ i ) its corresponding standard error, i = 1, . . . , 13; these are numbers described in Table 1 . For a fixed r > 0, consider the set S r of 13-tuples (ϑ 1 , . . . , ϑ 13 ) for which the ratio (θ i − ϑ i )/se(θ i ) is either r or −r for all i. That is, S r is the set of all possible combinations of potentially true parameter values that are at a distance of r standard errors from their corresponding estimates.
Observe that, for fixed r, S r has 2 13 = 8192 elements.
As in Section 5, we used a target plasma clozapine concentration range of 350-600 ng/ml; and p 3 and q 3 were defined as the proportion of patients who reached this range after 2 dosage adjustments using Diaz et al.'s algorithm and formula (10) Table 1 were entered into formulas (4)- (7). (The parameter estimates were not used to compute dosages with the traditional TDM approach, since formula (10) does not require them.) As in Section 5, the initial dosages used in both individualization procedures were those shown in Table 2 , and we let C 0 = C * 0 in formula (10).
For fixed r, the number of elements of S r for which p 3 > q 3 was computed, divided by 2 13 and multiplied by 100; the resultant percentage, denoted by Ω r , was interpreted as the proportion of potentially true parameter combinations in S r under which Diaz et al.'s algorithm outperformed formula (10) after 2 dosage adjustments. Table 4 shows Ω r for all subpopulations and particular values of r. Remarkably, for all patient subpopulations, Ω r > 98% when r ≤ 1.2. (Regardless of the subpopulation investigated, Ω r = 100% when r ≤ 1.) Another computation showed that, when r ≤ 1, the average of the differences p 3 − q 3 , taken over all elements of S r was ≥ 8.6%. This suggests that, even if all true parameters are at a distance of 1 standard error from their corresponding estimates in Table 1 (Table 4) . However, even when r = 1.6, which is an appreciable distance between an estimate and its corresponding parameter, Ω r was relatively large in most subpopulations of patients (Table   4 ). In fact, for 56 out of the 64 subpopulations, Ω 1.6 ≥ 80%; for all subpopulations,
We conclude that if the true values of the parameters of the clozapine model reported in Table 1 are not very far from the reported estimates (i.e., ≤ 1. 
Discussion
This article examines the algorithm proposed by Diaz et al. (2007) , which is a rational approach to computing individualized optimum dosages that is based on a precise definition of dosage optimality. Diaz et al. (2007) assumed that the patient belongs to a population that can be described by model (1) . This model represents patients' heterogeneity through both covariates and a random intercept. As described in Section 2, the algorithm can be applied to a more general situation, described by model (2), which has 2 additional features: covariates with random effects that add more flexibility these parameter estimates are combined with measurements from a particular patient in order to compute a dosage that is optimum for the patient with a high probability.
Parameter estimates are also used in these dosage adjustments.
There is empirical evidence that model (2) A reasonable explanation for the above similarity between results from model (2) and those from compartmental models may be that, in the case of Y D being steadystate drug plasma concentration, model (2) 
Conclusion
The main conclusion of this investigation is that, if model (2) years at the University of Kansas, Kansas City, KS.
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